Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Epidemiology of Cancer in Europe—What Are the Trends?

December 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

"There is both good and bad news about cancer in Europe,” said Dr. Peter Boyle of the European Institute of Oncology, Milan, Italy, at the 1997 European Cancer Conference. “One welcome development is the large decrease in the incidence of

"There is both good and bad news about cancer in Europe,” said Dr. Peter Boyle of the European Institute of Oncology, Milan, Italy, at the 1997 European Cancer Conference. “One welcome development is the large decrease in the incidence of stomach cancer in all parts of Europe, but unfortunately, the increasing age of the European Union (EU) population is linked with an increasing number of cases of cancer in total, with large increases in the incidence of Hodgkin’s lymphoma and malignant melanoma. In the next 15 years the proportion of people age 65 or over is likely to rise from 15% to 17%, a rise that will be matched by a similar fall in the 15 to 64 age group.”

“Levels of lung cancer and other smoking related cancers are high and still increasing, particularly in central and eastern Europe,” continued Dr. Boyle. “An epidemic of lung cancer is threatening women in southern Europe and this will pose a major problem for health services in coming decades.”

Dr. Boyle makes a strong call to action: “With our current knowledge, we could eliminate at least half of all cancers. We need to take practical steps to do this, rather than just discuss it.” 

Articles in this issue

Breast Cancer Treatment in Europe
The Sidney Kimmel Foundation for Cancer Research Seeks 1998 Scholar Applicants
New Study Shows Processed Tomato Products Are a Better Source of Lycopene Than Fresh Tomatoes
New Endocrine Treatments for Prostate Cancer
FDA Grant Given to Continue Studies of Aminopterin
American Association for Cancer Research 1998 Research Fellowships
Breast Cancer: The Importance of Local Control
Screening for Prostate Cancer-The European View
Testosterone Levels Early in Life May Determine Later Risk of Prostate Cancer
The Surgeon and Surgical Procedure as Prognostic Factors
Clinical Trial of New Agent to Overcome MDR Resistance in Multiple Myeloma Patients
Epidemiology of Cancer in Europe—What Are the Trends?
Surgical Outcomes in Gastric Cancer
Combined-Modality Therapy for Head and Neck Cancer
Study Suggests Smoking Is Associated with Chromosome Loss

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
2 experts in this video
Related Content

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

Tim Cortese
July 11th 2025
Article

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


For the First Time, A Nilotinib Without Fasting Restrictions

For the First Time, A Nilotinib Without Fasting Restrictions

July 11th 2025
Article

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


HTMC0435 plus temozolomide led to an ORR of 24.5%, with a median OS of 12.0 months, in patients with platinum-sensitive and platinum-resistant small cell lung cancer.

HTMC0435 Plus Chemotherapy Yields Responses in Relapsed ES-SCLC

Tim Cortese
July 11th 2025
Article

HTMC0435 plus temozolomide led to an ORR of 24.5%, with a median OS of 12.0 months, in patients with platinum-sensitive and platinum-resistant small cell lung cancer.


The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Denosumab Biosimilars Available in the US for Bone Mets, Multiple Myeloma

Roman Fabbricatore
July 10th 2025
Article

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Related Content

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

Tim Cortese
July 11th 2025
Article

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


For the First Time, A Nilotinib Without Fasting Restrictions

For the First Time, A Nilotinib Without Fasting Restrictions

July 11th 2025
Article

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


HTMC0435 plus temozolomide led to an ORR of 24.5%, with a median OS of 12.0 months, in patients with platinum-sensitive and platinum-resistant small cell lung cancer.

HTMC0435 Plus Chemotherapy Yields Responses in Relapsed ES-SCLC

Tim Cortese
July 11th 2025
Article

HTMC0435 plus temozolomide led to an ORR of 24.5%, with a median OS of 12.0 months, in patients with platinum-sensitive and platinum-resistant small cell lung cancer.


The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Denosumab Biosimilars Available in the US for Bone Mets, Multiple Myeloma

Roman Fabbricatore
July 10th 2025
Article

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.